Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
7% year-over-year growth in fourth quarter global procedures and recurring revenueSubstantial progress in delineating and initiating strategic innovation plansIncreasing quantity and quality of...
-
Enables continued execution of innovation and commercial initiativesNon-dilutive to shareholdersLong term lock-up agreement on exercised warrantsRepresents necessary first step on path to relist on...
-
ST. LOUIS, March 02, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it...
-
Stereotaxis technology included in recommendations to reduce fluoroscopy exposure and described as allowing “near zero exposure” to electrophysiologistsClinical data demonstrates significant reduction...
-
Revenue of $7.6 million for the fourth quarter and $31.2 million for the full year 2017Fourth quarter year-over-year revenue growth of 4% and procedure growth of 5% ST. LOUIS, Jan. 08, 2018 (GLOBE...
-
ST. LOUIS, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it...
-
ST. LOUIS, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David...
-
3% year-over-year growth in recurring revenue and 2% year-over-year growth in global proceduresReduced operating expenses leads to small quarterly operating profitSubstantial progress on strategic...
-
ST. LOUIS, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will...
-
ST. LOUIS, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that...